Mid-Term Strategy

Maximizing Product VALUE and Operational Excellence

Maximizing Product VALUE

Astellas will work to maximize product VALUE by intensively allocating resources to XTANDI, mirabegron and six key post-POC pipeline projects.

With regard to XTANDI, particularly its indication for metastatic castration-resistant prostate cancer, Astellas will strive to further increase penetration of XTANDI amongst urologists, along with establishing it as the first choice of therapy by utilizing extensive data based on the clinical experience accumulated since its launch. Moreover, we aim to expand the patient base and duration of therapy for XTANDI by expanding indications to earlier stages of prostate cancer.

In the OAB franchise, Astellas will work to mitigate the impact of the loss of exclusivity of VESIcare by shifting sales resources to mirabegron. We will continue to educate the public on mirabegron’s clinical profile featuring a balance of efficacy and safety, with the aim of expanding market share.

In addition to maximizing the VALUE of these products, we will preferentially direct management resources to six key post-POC pipeline projects in order to obtain approval of these products as planned and support growth from fiscal 2020 onward.

Global Sales (March 2018 to March 2021)

Chart:Global Sales (March 2018 to March 2021)

Six Key Post-POC Pipeline Projects

Chart:Six Key Post-POC Pipeline Projects

Pursuing Operational Excellence

Astellas will review all activities from a zero-basis from many different angles, without relying on past precedent.

Specifically, Astellas will preferentially allocate management resources to functions and activities that establish its competitive advantage over other companies, while terminating investment in areas that will not lead to growth or the establishment of competitiveness. In addition, Astellas will work to further evolve the operating model by leveraging cutting-edge technologies such as robotic process automation (RPA) and artificial intelligence (AI), and through globalization of organizations and functions and the standardization of operating processes.

Astellas anticipates an improvement of more than ¥30.0 billion in core operating profit to be generated from new initiatives in fiscal 2020.

Our Approach to Operational Excellence

Chart:Our Approach to Operational Excellence
Button: Return to top of page